AG˹ٷ

STOCK TITAN

[Form 4] Quince Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Quince Therapeutics, Inc. (QNCX) � Form 4 insider transaction

Chief Business, Operations and Commercial Officer Brendan Hannah reported a purchase of company securities on 18 June 2025.

  • Common shares acquired: 37,736 shares
  • Purchase price: $1.20 per share
  • Post-transaction direct ownership: 334,276 common shares
  • Derivative securities acquired: 37,736 warrants with a $1.20 exercise price, expiring 18 June 2030; cost recorded at $0.125 per warrant

The filing indicates a straightforward insider purchase (Transaction Code “A�) rather than a sale or option exercise. No other changes to ownership structure or additional transactions were disclosed.

Materiality assessment: The transaction increases Hannah’s direct equity stake by approximately 11 % (37,736 ÷ 334,276 � 11 %), but the absolute dollar value is relatively modest (� $45,000 for the shares, � $4,700 for the warrants). There is no indication of broader strategic developments, earnings information, or company-level financial impact within this filing.

Quince Therapeutics, Inc. (QNCX) � Transazione interna Form 4

Brendan Hannah, Chief Business, Operations and Commercial Officer, ha segnalato l'acquisto di titoli della società in data 18 giugno 2025.

  • Azioni ordinarie acquistate: 37.736 azioni
  • Prezzo di acquisto: 1,20 $ per azione
  • Partecipazione diretta post-transazione: 334.276 azioni ordinarie
  • Strumenti derivati acquisiti: 37.736 warrant con prezzo di esercizio di 1,20 $, in scadenza il 18 giugno 2030; costo registrato di 0,125 $ per warrant

La comunicazione indica un acquisto diretto da parte di un insider (Codice Transazione “A�) e non una vendita o esercizio di opzioni. Non sono state rivelate altre modifiche nella struttura proprietaria o ulteriori operazioni.

Valutazione di rilevanza: L'operazione aumenta la partecipazione diretta di Hannah di circa l'11% (37.736 ÷ 334.276 � 11%), ma il valore assoluto in dollari è relativamente contenuto (circa 45.000 $ per le azioni, circa 4.700 $ per i warrant). Non vi sono indicazioni di sviluppi strategici più ampi, informazioni sugli utili o impatti finanziari a livello aziendale in questa comunicazione.

Quince Therapeutics, Inc. (QNCX) � Transacción interna Formulario 4

Brendan Hannah, Director de Negocios, Operaciones y Comercial, reportó la compra de valores de la empresa el 18 de junio de 2025.

  • Acciones ordinarias adquiridas: 37,736 acciones
  • Precio de compra: 1.20 $ por acción
  • Propiedad directa después de la transacción: 334,276 acciones ordinarias
  • Valores derivados adquiridos: 37,736 warrants con precio de ejercicio de 1.20 $, con vencimiento el 18 de junio de 2030; costo registrado de 0.125 $ por warrant

El informe indica una compra directa por parte de un insider (Código de Transacción “A�) en lugar de una venta o ejercicio de opción. No se divulgaron otros cambios en la estructura de propiedad ni transacciones adicionales.

Evaluación de materialidad: La transacción incrementa la participación directa de Hannah aproximadamente en un 11 % (37,736 ÷ 334,276 � 11 %), pero el valor absoluto en dólares es relativamente modesto (aprox. 45,000 $ por las acciones, aprox. 4,700 $ por los warrants). No hay indicios de desarrollos estratégicos más amplios, información sobre ganancias o impacto financiero a nivel corporativo en este informe.

Quince Therapeutics, Inc. (QNCX) � Form 4 내부� 거래 보고

최고 비즈니스, 운영 � 상업 책임� 브렌� 해나� 2025� 6� 18� 회사 증권� 매수했다� 보고했습니다.

  • 취득� 보통�: 37,736�
  • 매수 가�: 주당 1.20달러
  • 거래 � 직접 보유 주식 �: 334,276�
  • 취득� 파생 증권: 행사가 1.20달러, 만기 2030� 6� 18일인 37,736 워런�; 워런� � 0.125달러� 비용 기록

해당 신고� 매도� 옵션 행사 대� 단순 내부� 매수(거래 코드 “A�)� 나타냅니�. 소유 구조 변경이� 추가 거래� 공개되지 않았습니�.

중요� 평가: 이번 거래� 해나� 직접 지분이 � 11% 증가했으�(37,736 ÷ 334,276 � 11%), 절대 금액은 비교� 적은 편입니다(주식 � 45,000달러, 워런� � 4,700달러). 이번 신고서에� 광범위한 전략� 변�, 수익 정보 또는 회사 차원� 재무 영향� 대� 언급� 없습니다.

Quince Therapeutics, Inc. (QNCX) � Transaction d’initié Formulaire 4

Brendan Hannah, Directeur des affaires, des opérations et du commercial, a déclaré un achat de titres de la société le 18 juin 2025.

  • Actions ordinaires acquises : 37 736 actions
  • Prix d'achat : 1,20 $ par action
  • Participation directe après la transaction : 334 276 actions ordinaires
  • Titres dérivés acquis : 37 736 bons de souscription avec un prix d’exercice de 1,20 $, expirant le 18 juin 2030 ; coût enregistré à 0,125 $ par bon

Le dépôt indique un achat direct par un initié (Code de transaction « A ») plutôt qu’une vente ou un exercice d’option. Aucun autre changement dans la structure de propriété ou transaction supplémentaire n’a été divulgué.

Évaluation de la matérialité : La transaction augmente la participation directe de Hannah d’environ 11 % (37 736 ÷ 334 276 � 11 %), mais la valeur absolue en dollars reste relativement modeste (environ 45 000 $ pour les actions, environ 4 700 $ pour les bons). Il n’y a aucune indication de développements stratégiques plus larges, d’informations sur les bénéfices ou d’impact financier au niveau de l’entreprise dans ce dépôt.

Quince Therapeutics, Inc. (QNCX) � Form 4 Insider-Transaktion

Brendan Hannah, Chief Business, Operations and Commercial Officer, meldete am 18. Juni 2025 den Kauf von Unternehmenswertpapieren.

  • Erworbene Stammaktien: 37.736 Aktien
  • Kaufpreis: 1,20 $ pro Aktie
  • Direkter Besitz nach der Transaktion: 334.276 Stammaktien
  • Erworbene Derivate: 37.736 Warrants mit einem Ausübungspreis von 1,20 $, Laufzeit bis 18. Juni 2030; Kosten mit 0,125 $ pro Warrant verbucht

Die Meldung weist auf einen einfachen Insider-Kauf (Transaktionscode „A�) hin, nicht auf einen Verkauf oder eine Optionsausübung. Keine weiteren Änderungen in der Eigentümerstruktur oder zusätzliche Transaktionen wurden offengelegt.

ѲٱäٲɱٳܲԲ: Die Transaktion erhöht Hannahs direkten Aktienanteil um etwa 11 % (37.736 ÷ 334.276 � 11 %), der absolute Geldwert ist jedoch relativ gering (ca. 45.000 $ für die Aktien, ca. 4.700 $ für die Warrants). Es gibt keine Hinweise auf umfassendere strategische Entwicklungen, Gewinninformationen oder finanzielle Auswirkungen auf Unternehmensebene in dieser Meldung.

Positive
  • Insider purchase: Officer acquired 37,736 common shares, often interpreted as a vote of confidence.
Negative
  • None.

Insights

TL;DR: Small insider buy suggests confidence; immaterial to fundamentals.

The Form 4 shows Brendan Hannah adding 37,736 common shares and an equal number of warrants. While insider buying is generally viewed as a constructive signal, the dollar size is minor relative to Quince Therapeutics� market capitalization and daily trading volumes. The warrant terms (five-year tenor, $1.20 strike) mildly align the officer with shareholder upside. However, the filing contains no information on operational performance or strategic actions, so investors should treat the signal as incrementally positive, not thesis-changing.

Quince Therapeutics, Inc. (QNCX) � Transazione interna Form 4

Brendan Hannah, Chief Business, Operations and Commercial Officer, ha segnalato l'acquisto di titoli della società in data 18 giugno 2025.

  • Azioni ordinarie acquistate: 37.736 azioni
  • Prezzo di acquisto: 1,20 $ per azione
  • Partecipazione diretta post-transazione: 334.276 azioni ordinarie
  • Strumenti derivati acquisiti: 37.736 warrant con prezzo di esercizio di 1,20 $, in scadenza il 18 giugno 2030; costo registrato di 0,125 $ per warrant

La comunicazione indica un acquisto diretto da parte di un insider (Codice Transazione “A�) e non una vendita o esercizio di opzioni. Non sono state rivelate altre modifiche nella struttura proprietaria o ulteriori operazioni.

Valutazione di rilevanza: L'operazione aumenta la partecipazione diretta di Hannah di circa l'11% (37.736 ÷ 334.276 � 11%), ma il valore assoluto in dollari è relativamente contenuto (circa 45.000 $ per le azioni, circa 4.700 $ per i warrant). Non vi sono indicazioni di sviluppi strategici più ampi, informazioni sugli utili o impatti finanziari a livello aziendale in questa comunicazione.

Quince Therapeutics, Inc. (QNCX) � Transacción interna Formulario 4

Brendan Hannah, Director de Negocios, Operaciones y Comercial, reportó la compra de valores de la empresa el 18 de junio de 2025.

  • Acciones ordinarias adquiridas: 37,736 acciones
  • Precio de compra: 1.20 $ por acción
  • Propiedad directa después de la transacción: 334,276 acciones ordinarias
  • Valores derivados adquiridos: 37,736 warrants con precio de ejercicio de 1.20 $, con vencimiento el 18 de junio de 2030; costo registrado de 0.125 $ por warrant

El informe indica una compra directa por parte de un insider (Código de Transacción “A�) en lugar de una venta o ejercicio de opción. No se divulgaron otros cambios en la estructura de propiedad ni transacciones adicionales.

Evaluación de materialidad: La transacción incrementa la participación directa de Hannah aproximadamente en un 11 % (37,736 ÷ 334,276 � 11 %), pero el valor absoluto en dólares es relativamente modesto (aprox. 45,000 $ por las acciones, aprox. 4,700 $ por los warrants). No hay indicios de desarrollos estratégicos más amplios, información sobre ganancias o impacto financiero a nivel corporativo en este informe.

Quince Therapeutics, Inc. (QNCX) � Form 4 내부� 거래 보고

최고 비즈니스, 운영 � 상업 책임� 브렌� 해나� 2025� 6� 18� 회사 증권� 매수했다� 보고했습니다.

  • 취득� 보통�: 37,736�
  • 매수 가�: 주당 1.20달러
  • 거래 � 직접 보유 주식 �: 334,276�
  • 취득� 파생 증권: 행사가 1.20달러, 만기 2030� 6� 18일인 37,736 워런�; 워런� � 0.125달러� 비용 기록

해당 신고� 매도� 옵션 행사 대� 단순 내부� 매수(거래 코드 “A�)� 나타냅니�. 소유 구조 변경이� 추가 거래� 공개되지 않았습니�.

중요� 평가: 이번 거래� 해나� 직접 지분이 � 11% 증가했으�(37,736 ÷ 334,276 � 11%), 절대 금액은 비교� 적은 편입니다(주식 � 45,000달러, 워런� � 4,700달러). 이번 신고서에� 광범위한 전략� 변�, 수익 정보 또는 회사 차원� 재무 영향� 대� 언급� 없습니다.

Quince Therapeutics, Inc. (QNCX) � Transaction d’initié Formulaire 4

Brendan Hannah, Directeur des affaires, des opérations et du commercial, a déclaré un achat de titres de la société le 18 juin 2025.

  • Actions ordinaires acquises : 37 736 actions
  • Prix d'achat : 1,20 $ par action
  • Participation directe après la transaction : 334 276 actions ordinaires
  • Titres dérivés acquis : 37 736 bons de souscription avec un prix d’exercice de 1,20 $, expirant le 18 juin 2030 ; coût enregistré à 0,125 $ par bon

Le dépôt indique un achat direct par un initié (Code de transaction « A ») plutôt qu’une vente ou un exercice d’option. Aucun autre changement dans la structure de propriété ou transaction supplémentaire n’a été divulgué.

Évaluation de la matérialité : La transaction augmente la participation directe de Hannah d’environ 11 % (37 736 ÷ 334 276 � 11 %), mais la valeur absolue en dollars reste relativement modeste (environ 45 000 $ pour les actions, environ 4 700 $ pour les bons). Il n’y a aucune indication de développements stratégiques plus larges, d’informations sur les bénéfices ou d’impact financier au niveau de l’entreprise dans ce dépôt.

Quince Therapeutics, Inc. (QNCX) � Form 4 Insider-Transaktion

Brendan Hannah, Chief Business, Operations and Commercial Officer, meldete am 18. Juni 2025 den Kauf von Unternehmenswertpapieren.

  • Erworbene Stammaktien: 37.736 Aktien
  • Kaufpreis: 1,20 $ pro Aktie
  • Direkter Besitz nach der Transaktion: 334.276 Stammaktien
  • Erworbene Derivate: 37.736 Warrants mit einem Ausübungspreis von 1,20 $, Laufzeit bis 18. Juni 2030; Kosten mit 0,125 $ pro Warrant verbucht

Die Meldung weist auf einen einfachen Insider-Kauf (Transaktionscode „A�) hin, nicht auf einen Verkauf oder eine Optionsausübung. Keine weiteren Änderungen in der Eigentümerstruktur oder zusätzliche Transaktionen wurden offengelegt.

ѲٱäٲɱٳܲԲ: Die Transaktion erhöht Hannahs direkten Aktienanteil um etwa 11 % (37.736 ÷ 334.276 � 11 %), der absolute Geldwert ist jedoch relativ gering (ca. 45.000 $ für die Aktien, ca. 4.700 $ für die Warrants). Es gibt keine Hinweise auf umfassendere strategische Entwicklungen, Gewinninformationen oder finanzielle Auswirkungen auf Unternehmensebene in dieser Meldung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hannah Brendan

(Last) (First) (Middle)
C/O QUINCE THERAPEUTICS, INC.
611 GATEWAY BLVD., SUITE 273

(Street)
SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Quince Therapeutics, Inc. [ QNCX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CBO, COO & CCO
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 06/18/2025 A 37,736 A $1.2 334,276 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Warrants $1.2 06/18/2025 A 37,736 06/18/2025 06/18/2030 Common Shares 37,736 $0.125 37,736 D
Explanation of Responses:
/s/ Brendan Hannah 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Quince Therapeutics (QNCX) shares did Brendan Hannah buy?

37,736 common shares were acquired on 18 June 2025.

At what price were the QNCX shares purchased?

The reported purchase price was $1.20 per share.

What is Brendan Hannah’s total direct shareholding after the transaction?

He now directly owns 334,276 common shares.

Were any derivative securities involved in the transaction?

Yes, 37,736 warrants with a $1.20 strike price expiring 18 June 2030 were acquired at $0.125 per warrant.

What role does Brendan Hannah hold at Quince Therapeutics?

He serves as CBO, COO & CCO of the company.

Does the filing indicate any sale of QNCX shares?

No. The Form 4 only reports acquisitions; there were no dispositions.
Quince

NASDAQ:QNCX

QNCX Rankings

QNCX Latest News

QNCX Latest SEC Filings

QNCX Stock Data

83.43M
39.50M
13.52%
23.46%
5.77%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
SOUTH SAN FRANCISCO